Overcoming Vaccine Hesitancy in Black and Brown Communities

February 9, 2021 11:00 AM - 11:30 AM

Webinar, click "live-stream" button to view

Add to Calendar 2/9/2021 11:00:00 AM 2/9/2021 11:30:00 AM Overcoming Vaccine Hesitancy in Black and Brown Communities

The COVID-19 pandemic has put a spotlight on the health inequities that plague our nation and the lack of access to quality care for Black and Brown populations. But, beyond health inequity remains a culture of mistrust between these marginalized populations and the scientific and healthcare communities that is negatively impacting uptake of the vaccine among Black and Brown populations.

With many states prioritizing Black and Brown populations for COVID-19 vaccines, how can the life sciences and healthcare industry do a better job disseminating factual information throughout these marginalized communities so they can trust in science and feel confident taking the vaccine as soon as they are able?

Join our next Town Hall as we discuss how we can achieve these goals by elevating the voices of diverse leaders in science, and better explaining the scientific evidence that demonstrates the safety and benefit of the vaccines for Black and Brown populations.

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

Webinar, click "live-stream" button to view
Chief Development Officer at Rocket Pharma
Dr. José Trevejo is a physician-scientist and an infectious disease specialist who has spent his career pursuing his passion for leading research and development teams in the advancement of novel therapeutics for serious diseases. Prior to his current role as Chief Development Officer at Rocket Pharma, he was CEO at SmartPharm Therapeutics that is currently developing novel countermeasures for COVID-19. Prior to SmartPharm, Dr. Trevejo served as Vice President, Clinical Development at Cyclerion Therapeutics. Dr. Trevejo joined Ironwood/Cyclerion from Visterra, where he was a member of the Executive Team and lead the pre-clinical and clinical development of novel biologics for infectious diseases. While at Visterra he oversaw the transition to a clinical stage company as well as helped to secure a $215 million DHHS award to support development of a novel treatment for influenza. Prior to Visterra, he held clinical development leadership positions at Genentech and Vertex Pharmaceuticals. Before entering the biotechnology industry, he served as Instructor in Medicine at Harvard Medical School and was a Principal Biomedical Scientist at the Draper Laboratory working on novel diagnostics for tuberculosis and other infectious diseases. Dr. Trevejo completed his clinical training at BWH/BIDMC/Harvard Medical School and earned his M.D. and Ph.D. from the Tri-Institutional MD-PhD program at Cornell-Rockefeller-Sloan Kettering in New York.